🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Honored by our affiliation with these two OWL nominees for Visionary Leader - Jeannette Bankes, Aurion board member, and Eric Donnenfeld, MD, Aurion medical advisory board member. Congrats, you two! owlsite.org/about-owl/2022…

Great things can happen when people work well together. aurionbiotech.com/living-our-val…

We are hiring! Please join our fab company: fantastic people who are committed to restoring vision to patients with our life-changing cell therapy, fantastic locations (Seattle and Cambridge, MA), fantastic comp. What's not to love? aurionbiotech.com/open-positions/

.Aurion Biotech wins Prix Galien Award for corneal endothelial dystrophy cell therapy. bit.ly/3DWOtvv #PrixGalienAward #celltherapy #Ophthalmology #OncularNews

Congrats to the 2022 #PrixGalien “Best Startup in Pharmaceutical or Biotechnology Industry” winner Aurion Biotech for its patented cell therapy treatment for corneal endothelial disease. Learn more: galien.org/3TNl3FH

Arnaud Lacoste, Chief Scientific Officer at Aurion Biotech talks about the new cell therapy for corneal endothelial dystrophy and its potential to change corneal surgery 👀 bit.ly/3Mr8Ljj

Excited that Jon Sparks, JD, PhD joins Aurion as Chief Legal Officer! aurionbiotech.com/jonathan-spark…

Important milestone for millions of patients suffering from corneal endothelial disease aurionbiotech.com/aurion-biotech…

Terrific panel at Reuters Pharma USA 2023!

Congrats to our inspiring inventor, Prof Shigeru Kinoshita, for being named to the Power List!urldefense.proofpoint.com/v2/url?u=https…

Lacoste discussed the findings of the research Aurion Biotech presented at #ARVO2023, noting that the study provided evidence that AURN001 cells contribute to immune privilege in the anterior chamber of the eye. Watch now: ow.ly/WaKp50O1kKc

please that our chief scientific officer asked to speak to CGTLive! ow.ly/WaKp50O1kKc

ASCRS Live: Aurion BioTech shares 12-month data from our recent Escalón trial ophthalmologytimes.com/view/ascrs-liv…

Dr. Matt Giegengack presenting Escalon trial 12-month data here at ASCRS

Great companies, in great company! Honored for Aurion to share BioFuture Stage with Endpoints News [email protected], Sean Ainsworth Immusoft Corporation, Christine Silverstein Excision BioTherapeutics, Liz Wood @JuraBio to talk about the future of cell and gene therapy: how it will transform patient care.

Greg Kunst shares the Aurion Biotech story on cell therapy for endothelial corneal disease ⁦@OSNNewYork⁩

Terrific conversation on challenges of C&GT manufacturing in a changing world. #cgmesa2023

Edward J. Holland, MD, and Shigeru Kinoshita, MD, PhD, discuss the U.S. phase 1/2 trial for Aurion Biotech's AURN001 #celltherapy for #cornealedema, which was invented by Kinoshita and just dosed its first patient last month. Find out more 🔗: bit.ly/40teAnt

So proud that we have received this honor! aurionstaging.wpengine.com/aurion-regener…

Great companies are led by great people. Congrats to Greg Kunst and thanks to Puget Sound Business Journal for this Healthcare Leadership award! bizjournals.com/seattle/news/2…